IP Library Granted Patent US 9,200,073
Granted Patent B2
US 9,200,073 · App. 14/015,653 · Granted Dec 1, 2015

Diagnostic assays and kits for detection of folate receptor 1

Inventors: Christina N. Carrigan (Belmont, MA); Olga Ab (Millis, MA); Daniel Tavares (Natick, MA); Beni B. Wolf (Lexington, MA)
Assignee: ImmunoGen, Inc.
C07K16/28G01N33/566G01N33/57492G01N2333/705
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,200,073
App. No.
14/015,653
Granted
Dec 1, 2015
Kind
B2
Abstract

The invention generally relates to antibodies that bind to human folate receptor 1 and diagnostic assays for folate receptor 1-based therapies. Methods of using the antibodies to monitor therapy are further provided.

Claims (27)

1. An antibody or antigen-binding fragment thereof that specifically binds to the same FOLR1 epitope as, and competitively inhibits the binding to FOLR1 of, an antibody selected from the group consisting of:

(a) an antibody comprising the variable heavy chain polypeptide of SEQ ID NO:25 and the variable light chain polypeptide of SEQ ID NO:29;

(b) an antibody comprising the variable heavy chain polypeptide of SEQ ID NO:26 and the variable light chain polypeptide of SEQ ID NO:30;

(c) an antibody comprising the variable heavy chain polypeptide of SEQ ID NO:27 and the variable light chain polypeptide of SEQ ID NO:31; and

(d) an antibody comprising the variable heavy chain polypeptide of SEQ ID NO:28 and the variable light chain polypeptide of SEQ ID NO:32.

2. An immunoassay kit for detecting FOLR1 protein in a sample, the kit comprising: (a) a first reagent, wherein the first reagent is the antibody or antigen-binding fragment thereof of claim 1 , and (b) a second reagent, wherein the second reagent is a second antibody or antigen-binding fragment that specifically binds to FOLR1.

3. The immunoassay kit of claim 2 , wherein the second reagent comprises a chromogenic detection agent, a fluorogenic detection agent, an enzymatic detection agent, or an electrochemiluminescent detection reagent.

4. The immunoassay kit of claim 2 , wherein the second reagent is biotinylated.

5. The immunoassay kit of claim 2 , wherein the first reagent is immobilized on a solid support.

6. An antibody or antigen-binding fragment thereof that specifically binds to FOLR1 , wherein said antibody or antigen-binding fragment thereof comprises a heavy chain variable domain and a light chain variable domain, wherein:

(a) the heavy chain variable domain comprises the CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 1, 2, and 3, respectively, and the light chain variable domain comprises the CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 13, 14, and 15, respectively;

(b) the heavy chain variable domain comprises the CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 4, 5, and 6, respectively, and the light chain variable domain comprises the CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 16,17, and 18;

(c) the heavy chain variable domain comprises the CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 7, 8, and 9, respectively, and the light chain variable domain comprises the CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 19, 20, and 21; or

(d) the heavy chain variable domain comprises the CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 10, 11, and 12, respectively, and the light chain variable domain comprises the CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 22, 23, and 24.

7. The antibody or antigen-binding fragment thereof of claim 6 , wherein said antibody or antigen-binding fragment thereof is murine, humanized, chimeric, resurfaced, or human.

8. An immunoassay kit for detecting FOLR1 protein in a sample, the kit comprising: (a) a first reagent, wherein the first reagent is the antibody or antigen-binding fragment of claim 6 and wherein said antibody or antigen-binding fragment comprises the heavy chain variable domain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 1, 2, and 3, respectively, and the light chain variable domain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 13, 14, and 15, respectively and (b) a second reagent, wherein the second reagent is an antibody or antigen-binding fragment comprising the heavy chain variable domain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 4, 5, and 6, respectively, and the light chain variable domain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 16, 17, and 18, respectively.

9. The immunoassay kit of claim 8 , wherein the second reagent comprises a chromogenic detection agent, a fluorogenic detection agent, an enzymatic detection agent, or an electrochemiluminescent detection reagent.

10. The immunoassay kit of claim 8 , wherein the second reagent is biotinylated.

11. The immunoassay kit of claim 8 , wherein the first reagent is immobilized on a solid support.

12. An antibody or antigen-binding fragment thereof that specifically binds to the same FOLR1 epitope as, and competitively inhibits the binding of an antibody comprising the variable heavy chain polypeptide of SEQ ID NO:25 and the variable light chain polypeptide of SEQ ID NO:29 to FOLR1.

13. An antibody or antigen-binding fragment thereof that specifically binds to FOLR1, wherein said antibody or antigen-binding fragment thereof comprises the heavy chain variable domain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 1, 2, and 3, respectively, and the light chain variable domain CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 13, 14, and 15, respectively.

14. An antibody or antigen-binding fragment thereof that specifically binds to FOLR1, wherein said antibody or antigen-binding fragment comprises a heavy chain variable domain and a light chain variable domain, wherein the light chain variable domain comprises the sequence set forth in SEQ ID NO:29 and the heavy chain variable domain comprises the sequence set forth in SEQ ID NO:25.

15. An antibody or antigen-binding fragment thereof that specifically binds to FOLR1, wherein said antibody or antigen-binding fragment thereof comprises a heavy chain variable domain and a light chain variable domain, wherein said heavy chain variable domain and said light chain variable domain comprise the sequences set forth in

(a) SEQ ID NO: 25 and SEQ ID NO:29, respectively;

(b) SEQ ID NO: 26 and SEQ ID NO:30, respectively;

(c) SEQ ID NO:27 and SEQ ID NO:31, respectively;

(d) SEQ ID NO:28 and SEQ ID NO:32, respectively.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Feb 12, 2024
From: BIOPHARMA CREDIT PLC
To: IMMUNOGEN, INC.; IMMUNOGEN SWITZERLAND GMBH
Reel/Frame 066553/0109 →
PATENT SECURITY AGREEMENT Recorded Apr 6, 2023
From: IMMUNOGEN, INC.; IMMUNOGEN SWITZERLAND GMBH
To: BIOPHARMA CREDIT PLC
Reel/Frame 063282/0894 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 8, 2015
From: CARRIGAN, CHRISTINA N.; AB, OLGA; TAVARES, DANIEL; WOLF, BENI B.
To: IMMUNOGEN, INC.
Reel/Frame 036759/0128 →
Continuity (3)
Provisional Application 61695791 · Aug 31, 2012
Provisional Application 61756254 · Jan 24, 2013
Related Publication 20140099332A1 · Apr 10, 2014